Cedars-Sinai Cancer | Strategic Alliance Partners

Dr. Chaudhary and Dr. Merin discuss potential areas for exploration and unmet needs in the chronic GvHD treatment landscape.

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.

Cedars-Sinai Cancer investigators elucidate how this process allows bladder tumors to evade the immune system but also makes them vulnerable to a common treatment.

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

Joshua P. Sasine, MD, PhD, discusses the potential role of cilta-cel in earlier lines of therapy for patients with multiple myeloma.

David R. Oveisi, MD, discusses the evolution and potential role of bispecific antibodies in multiple myeloma, and presents several areas of unmet need regarding their use in this space.

Yuan Yuan, MD, PhD, discusses the OptimICE-pCR trial and other ongoing clinical trials in breast cancer being conducted at Cedars-Sinai, and expands on the role of CDK4/6 inhibitors and other novel treatment strategies for patients with hormone receptor-positive breast cancer.

Physicians at Cedars-Sinai Cancer are using a unique chemotherapy delivery system that offers hope to colorectal cancer patients whose disease has spread and who now have inoperable liver tumors.

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.

Before sharing clinical pearls for the treatment of prostate cancer, key opinion leaders reflect on the potential use of immune checkpoint inhibitors in mCRPC.

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Key opinion leaders reflect on data from the TITAN and PEACE-1 clinical trials, respectively, in the setting of metastatic hormone-sensitive prostate cancer.

Shared insight on the ENZAMET and ARCHES clinical trials, which utilized combination enzalutamide strategies in patients with metastatic hormone-sensitive prostate cancer.

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

Vitamin D deficiency could be the reason African American men experience more aggressive prostate cancer at a younger age compared with European American men.

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

Investigators from Cedars-Sinai Cancer are collaborating on a streamlined clinical trial design in a study called Pragmatica-Lung.

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.

A brief discussion on the role of quality of life in selecting best therapy for patients with non-metastatic castration-resistant prostate cancer.

Key opinion leaders reflect on the real-world use and data behind AR inhibitors in non-metastatic castration-resistant prostate cancer.

Shared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.

Expert oncologists provide a focused review on goals of therapy for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).